Drotrecogin alfa on trial.
Tillotson
Glenn S
GS
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000592:standards*; D017277:Drug Approval; D005060:Europe; D006801:Humans; D011358:Product Surveillance, Postmarketing; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*; D014481:United States
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated